Patents by Inventor John A. Wichtowski
John A. Wichtowski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20020065219Abstract: Novel thiazolyl peptide compounds useful for the treatment of serious bacterial infections, and pharmaceutical compositions thereof are provided.Type: ApplicationFiled: August 13, 2001Publication date: May 30, 2002Inventors: B. Narasimhulu Naidu, Wenying Li, Kin S. Lam, Margaret E. Sorenson, John A. Wichtowski, Timothy P. Connolly, Yasutsugu Ueda, Joanne J. Bronson, Yunhui Zhang, Oak K. Kim
-
Patent number: 6169082Abstract: This invention presents alkali metal salts of 8,9-dehydroestrone, salts of its sulfate ester, and stable compositions thereof, as well as processes for their production and use in estrogen replacement therapy and cardiovascular protection.Type: GrantFiled: February 18, 1993Date of Patent: January 2, 2001Assignee: American Home Products CorporationInventors: Panolil C. Raveendranath, John A. Wichtowski
-
Patent number: 5734047Abstract: Novel cephem derivatives represented by the general formula ##STR1## wherein Ar is an optionally substituted lipophilic phenyl, naphthyl, benzthiazolyl or pyridyl group; R.sup.1 represents a group of the formula ##STR2## in which R.sup.8 and R.sup.9 are each independently hydrogen, C.sub.1 -C.sub.6 alkyl or (C.sub.1 -C.sub.6)alkoxycarbonyl, said C.sub.1 -C.sub.6 alkyl group being optionally substituted by 1-5 hydroxy or C.sub.1 -C.sub.6 alkoxy groups; m is either 0 or 1; A is a C.sub.2 -C.sub.10 alkyl group optionally substituted by 1-5 hydroxy groups; and R.sup.2 and R.sup.3 are each independently hydrogen or C.sub.1 -C.sub.6 alkyl. The derivatives are gram-positive antibacterial agents especially useful in the treatment of diseases caused by methicillin-resistant Staphylococcus aureus.Type: GrantFiled: December 5, 1996Date of Patent: March 31, 1998Assignee: Bristol-Myers Squibb CompanyInventors: Choung U. Kim, Muzammil M. Mansuri, Peter F. Misco, John A. Wichtowski
-
Patent number: 5668290Abstract: Novel cephem derivatives represented by the general formula ##STR1## in which the Acyl substituent is a group of the formula ##STR2## wherein Ar is a lipophilic optionally substituted phenyl, naphthyl or pyridyl group; R.sup.1 represents either the residue of a heterocyclic amino acid or a C.sub.2 -C.sub.10 alkyl group substituted by both a carboxyl group and a group of the formula --NR.sup.9 R.sup.10 or ##STR3## in which R.sup.9 and R.sup.10 are each independently hydrogen or C.sub.1 -C.sub.6 alkyl, said C.sub.2 -C.sub.10 alkyl group being optionally interrupted by one or more nitrogen atoms or carbonyl groups, and R.sup.2 and R.sup.3 are each independently hydrogen, alkyl or aminoalkyl are gram-positive antibacterial agents, especially useful in the treatment of diseases caused by methicillin-resistant Staphylococcus aureus (also referred to below as MRSA or methicillin-resistant S. aureus).Type: GrantFiled: August 23, 1996Date of Patent: September 16, 1997Assignee: Bristol-Myers Squibb CompanyInventors: Joanne J. Bronson, Stanley V. D'Andrea, Shelley E. Hoeft, John D. Matiskella, Peter F. Misco, Jr., Bing Yu Luh, Dane M. Springer, Yasutsugu Ueda, John A. Wichtowski
-
Patent number: 5668284Abstract: Novel cephem derivatives represented by the general formula ##STR1## in which the Acyl substituent is a group of the formula ##STR2## wherein Ar is a lipophilic optionally substituted phenyl, naphthyl, pyridyl or benzthiazolyl group; R.sup.1 is selected from certain optionally substituted aliphatic, aromatic, arylaliphatic or sugar moieties and R.sup.2 and R.sup.3 are each independently hydrogen, alkyl or aminoalkylcarbonylamino are gram-positive antibacterial agents, especially useful in the treatment of infectious diseases caused by methicillin-resistant Staphylococcus aureus (MRSA).Type: GrantFiled: May 8, 1996Date of Patent: September 16, 1997Assignee: Bristol-Myers Squibb CompanyInventors: Choung U. Kim, Peter F. Misco, Jr., John A. Wichtowski, Yasutsugu Ueda, Thomas W. Hudyma, John D. Matiskella, Stanley V. D'Andrea, Shelley E. Hoeft, Raymond F. Miller, Muzammil M. Mansuri, Joanne J. Bronson
-
Patent number: 5620969Abstract: Novel cephem derivatives represented by the general formula ##STR1## in which the Acyl substituent is a group of the formula ##STR2## wherein Ar is a lipophilic optionally substituted phenyl, naphthyl or pyridyl group; R.sup.1 represents either the residue of a heterocyclic amino acid or a C.sub.2 -C.sub.10 alkyl group substituted by both a carboxyl group and a group of the formula --NR.sup.9 R.sup.10 or ##STR3## in which R.sup.9 and R.sup.10 are each independently hydrogen or C.sub.1 -C.sub.6 alkyl, said C.sub.2 -C.sub.10 alkyl group being optionally interrupted by one or more nitrogen atoms or carbonyl groups, and R.sup.2 and R.sup.3 are each independently hydrogen, alkyl or aminoalkyl are gram-positive antibacterial agents, especially useful in the treatment of diseases caused by methicillin-resistant Staphylococcus aureus (also referred to below as MRSA or methicillin-resistant S. aureus).Type: GrantFiled: April 25, 1995Date of Patent: April 15, 1997Assignee: Bristol-Myers Squibb CompanyInventors: Joanne J. Bronson, Stanley V. D'Andrea, Shelley E. Hoeft, John D. Matiskella, Peter F. Misco, Jr., Bing Y. Luh, Dane M. Springer, Yasutsugu Ueda, John A. Wichtowski
-
Patent number: 5567698Abstract: Novel cephem derivatives represented by the general formula ##STR1## in which the Acyl substituent is a group of the formula ##STR2## wherein Ar is a lipophilic optionally substituted phenyl, naphthyl, pyridyl or benzthiazolyl group; R.sup.1 is selected from certain optionally substituted aliphatic, aromatic, arylaliphatic or sugar moieties and R.sup.2 and R.sup.3 are each independently hydrogen, alkyl or aminoalkylcarbonylamino are gram-positive antibacterial agents, especially useful in the treatment of infectious diseases caused by methicillin-resistant Staphylococcus aureus (MRSA).Type: GrantFiled: May 30, 1995Date of Patent: October 22, 1996Assignee: Bristol-Myers Squibb CompanyInventors: Choung U. Kim, Peter F. Misco, Jr., John A. Wichtowski, Yasutsugu Ueda, Thomas W. Hudyma, John D. Matiskella, Stanley V. D'Andrea, Shelley E. Hoeft, Raymond F. Miller, Muzammil M. Mansuri, Joanne J. Bronson
-
Patent number: 5559108Abstract: Novel cephem derivatives represented by the general formula ##STR1## in which the Acyl substituent is a group of the formula ##STR2## where Ar is a substituted phenyl or optionally substituted naphthyl or benzthiazolyl group and A is a substituted-pyridinium group are gram-positive antibiotics, especially useful in the treatment of diseases caused by methicillin-resistant Staphylococcus aureus.Type: GrantFiled: May 22, 1995Date of Patent: September 24, 1996Assignee: Bristol-Myers Squibb CompanyInventors: Choung U. Kim, Muzammil M. Mansuri, Peter F. Misco, Jr., John A. Wichtowski, Joanne J. Bronson, Stanley V. D'Andrea, Thomas W. Hudyma
-
Patent number: 5288717Abstract: This invention presents alkali metal salts of 8,9-dehydroestrone, its sulfate ester, and stable compositions thereof, as well as processes for their production. The sulfate ester salts are useful in estrogen replacement therapy.Type: GrantFiled: December 3, 1992Date of Patent: February 22, 1994Assignee: American Home Products CorporationInventors: Panolil C. Raveendranath, John A. Wichtowski
-
Patent number: 5210081Abstract: This invention presents alkali metal salts of 8,9-dehydroestrone, its sulfate ester, and stable compositions thereof, as well as processes for their production. The sulfate ester salts are useful in estrogen replacement therapy.Type: GrantFiled: February 26, 1992Date of Patent: May 11, 1993Assignee: American Home Products CorporationInventors: Panolil C. Raveendranath, John A. Wichtowski